Form 4: Monte Rosa Therapeutics Executive Acquires 40,000 Stock Options

Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, acquired 40,000 stock options on June 3, 2024, at an exercise price of $3.98.

Summary

• On June 3, 2024, Jennifer Champoux, the Chief Operating Officer of Monte Rosa Therapeutics, acquired 40,000 stock options.
• The exercise price for these options is $3.98 per share.
• The options vest over time, with 25% vesting on May 28, 2025, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• The expiration date for these options is June 3, 2034.
• Following the transaction, Ms. Champoux directly owns 40,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, suggesting confidence from the executive in the company's future.

Positives

• The acquisition of stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule suggests a long-term commitment from the COO, aligning her interests with the company's future success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The stock option grant aligns the COO's interests with those of shareholders, incentivizing her to drive long-term value creation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership team.

Key Dates